Advertisement

Menopause and Bone Metabolism

  • ML. BrandiEmail author
  • L. Di Medio
Living reference work entry
  • 6 Downloads
Part of the Endocrinology book series (ENDOCR)

Abstract

The hormonal changes that take place at menopause are the most important reason why women are at greater risk of osteoporosis than men.

Fragility fractures osteoporosis related are a relevant cause of disability and excess mortality in postmenopausal women.

General measures such as calcium and vitamin D supplementation or physical exercise could be very useful for prevention of fragility fractures.

The use of registered drugs is recommended when the health benefits overcome the risks. The FRAX® algorithm is a scientifically validated risk assessment tool that improves identification of patients at high risk of fracture.

Antiresorptive agents are the predominant therapeutic category for preventing fractures, and bisphosphonates are still the most commonly used. However, new and more effective therapies are nowadays available for prevention and treatment of bone loss.

Keywords

Postmenopause Osteoporosis Fragility fractures Antiosteoporotic therapy 

References

  1. Abrahamsen B, et al. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009a;24:1095–102.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Abrahamsen B, et al. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009b;265:581–92.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Baim S, et al. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24:561–74.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Barrett-Connor E, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Black DM, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353:555–65.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Black DM, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Black DM, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bone HG, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149–57.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Bunch TJ, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009;103:824–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Burghardt AJ, et al. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women witeh low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010;25:2558–71.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Chapurlat RD, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22:1502–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Collins P, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation. 2009;119:922–30.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Cosman F, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353:566–75.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Cosman F, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide (rhPTH(1–34)) in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503–11.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Cosman F, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.Google Scholar
  16. Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Cosman F, et al. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32:198–202.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Cosman F, et al. FRAME study: the foundation effect of building Bone with 1 year of Romosozumab leads to continued lower fracture risk after transition to Denosumab. J Bone Miner Res. 2018;33:1219–26.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Cranney A, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2009;20:291–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Cummings SR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Curtis JR, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008;19:1613–20.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Ensrud KE, et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for The Heart trial. J Bone Miner Res. 2008;23:112–20.CrossRefPubMedPubMedCentralGoogle Scholar
  23. EPOS Group, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis Int. 2002;13:565–71.CrossRefGoogle Scholar
  24. Eriksen EF, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24:1308–13.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Finkelstein JS, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838–45.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Genant H, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11(6):707–30.Google Scholar
  27. Gennari L, et al. Osteoporosis in men. Endocrinol Metab Clin North Am. 2007;36:399–419.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Haentjens P, On behalf of the Network on Male Osteoporosis in Europe (NEMO), et al. Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles’ or spine fracture: Colles’ fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res. 2004;19:1933–44.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Harris ST, et al. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237–45.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Hodsman AB, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688–703.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Hoff AO, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Johansson H, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28:775–80.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Johnell O, et al. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Int. 2006;17(12):1726–33. Epub 2006 Sep 16.Google Scholar
  34. Kanis JA, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35(2):375–82.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Kanis JA, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44:1049–54.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Kelley GA, et al. Exercise and bone mineral density in premenopausal women: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2013;2013:741639.PubMedPubMedCentralGoogle Scholar
  37. Kenneth G, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.CrossRefGoogle Scholar
  38. Lee S, et al. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22:741–53.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Leeming DJ, et al. An update on biomarkers of bone turnover and their utility in biochemical research and clinical practice. Eur J Clin Pharmacol. 2006;62:781–92.CrossRefGoogle Scholar
  40. Lips P, et al. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1):4–8.CrossRefGoogle Scholar
  41. Lyles KW, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.CrossRefPubMedPubMedCentralGoogle Scholar
  42. Magopoulos C, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007;28:158–63.CrossRefPubMedPubMedCentralGoogle Scholar
  43. Mbalaviele G, et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005;94:403–18.CrossRefPubMedPubMedCentralGoogle Scholar
  44. McClung MR, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–20.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Melton LJ III, et al. Epidemiology of vertebral fractures: implications for vertebral augmentation. Acad Ther. 2006;13:538–45.Google Scholar
  46. Meunier PJ, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20:1663–73.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Miller PD, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and re- starting of therapy: a randomized blinded phase2 clinical trial. Bone. 2008;43:222–9.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Miller PD, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Moreira LDF, et al. Physical exercise and osteoporosis: effects of different types of exercises on bone and physical function of postmenopausal women. Arq Bras Endocrinol Metabol. 2014;58(5):514–22.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Mosca L, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke. 2009;40:147–55.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Ominsky MS, et al. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014;29:1424–30.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Padhi D, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Papapoulos SE, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. 2005;16:468–74.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Pilbeam C, et al. Prostaglandins and bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic; 2002. p. 979–94.CrossRefGoogle Scholar
  55. Poole KE, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–4.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Prince R, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20:1507–13.CrossRefPubMedPubMedCentralGoogle Scholar
  57. Reginster JY, Rabenda V, et al. Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol. 2006;1(1):37–40.CrossRefGoogle Scholar
  58. Reid DM, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373:1253–63.CrossRefPubMedPubMedCentralGoogle Scholar
  59. Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Sambrook P, et al. Lancet. 2006;367:2010–8.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Seeman E, et al. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250–61.CrossRefPubMedPubMedCentralGoogle Scholar
  62. Silverman SL, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–34.CrossRefPubMedPubMedCentralGoogle Scholar
  63. Silverman SL, et al. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122(2 Suppl):S33–45.CrossRefPubMedPubMedCentralGoogle Scholar
  64. Silverman SL, et al. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int. 2011;22:21–6.CrossRefPubMedPubMedCentralGoogle Scholar
  65. Sorensen HT, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336:813–6.CrossRefPubMedPubMedCentralGoogle Scholar
  66. Tsai JN, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet. 2013;382:50–6.CrossRefPubMedPubMedCentralGoogle Scholar
  67. Tsai JN, et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength, the DATA-HRpQCT Study. J Bone Miner Res. 2015;30(1):39–45.CrossRefPubMedPubMedCentralGoogle Scholar
  68. van Bezooijen RL, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22:19–28.CrossRefPubMedPubMedCentralGoogle Scholar
  69. Weycker D, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int. 2006;17:1645.CrossRefGoogle Scholar
  70. Wijenayaka AR, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:25900.CrossRefGoogle Scholar
  71. Wilk A, et al. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int. 2014;25:2777–86.CrossRefPubMedPubMedCentralGoogle Scholar
  72. Yarom N, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007;18:1363–70.CrossRefPubMedPubMedCentralGoogle Scholar
  73. Zallone A, et al. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci. 2006;1068:173–9.CrossRefPubMedPubMedCentralGoogle Scholar
  74. Zanchetta JR, et al. Effects of teriparatide (recombinant human parathyroid hormone (1–34)) on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18:539–43.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.FirmoLab Fondazione F.I.R.M.OFlorenceItaly
  2. 2.University of Florence, Metabolic Bone Diseases Unit, University Hospital of FlorenceFlorenceItaly

Personalised recommendations